0000000000404411

AUTHOR

Tiziana Granata

0000-0002-0170-6836

showing 6 related works from this author

Suppressive Efficacy by a Commercially Available Blue Lens on PPR in 610 Photosensitive Epilepsy Patients

2006

Purpose Photosensitivity can represent a serious problem in epilepsy patients, also because pharmacologic treatment is often ineffective. Nonpharmacologic treatment using blue sunglasses is effective and safe in controlling photosensitivity, but large series of patients have never been studied. Methods This multicenter study was conducted in 12 epilepsy centers in northern, central, southern, and insular Italy. A commercially available lens, named Z1, obtained in a previous trial, was used to test consecutively enrolled pediatric and adult epilepsy patients with photosensitivity. Only type 4 photosensitivity (photoparoxysmal response, PPR) was considered in the study. A standardized method …

EPILEPSY-PHOTOSENSITIVE-BLUE GLASSES-NONPHARMACOLOGICAdultMalemedicine.medical_specialtyAdolescentEpilepsy ReflexPharmacological treatmentCentral nervous system diseaseEpilepsyPhotosensitive epilepsyInternal medicineFemale patientmedicineHumansPractice Patterns Physicians'ChildAgedbusiness.industryVideotape RecordingLarge seriesElectroencephalographyMiddle Agedmedicine.diseaseTREATMENT-PHOTOPAROXYSMAL RESPONSE-PPRSurgeryClinical trialTreatment OutcomeItalyNeurologyMulticenter studyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)PHOTOSENSITIVEEye Protective DevicesbusinessColor PerceptionPhotic StimulationEpilepsia
researchProduct

HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond

2018

International audience; Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels control neuronal excitability and their dysfunction has been linked to epileptogenesis but few individuals with neurological disorders related to variants altering HCN channels have been reported so far. In 2014, we described five individuals with epileptic encephalopathy due to de novo HCN1 variants. To delineate HCN1-related disorders and investigate genotype-phenotype correlations further, we assembled a cohort of 33 unpublished patients with novel pathogenic or likely pathogenic variants: 19 probands carrying 14 different de novo mutations and four families with dominantly inherited variants segre…

0301 basic medicineProbandMaleModels MolecularPotassium Channels[SDV]Life Sciences [q-bio]Medizinmedicine.disease_causeEpileptogenesisMembrane PotentialsEpilepsy0302 clinical medicineHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsMissense mutationChildGeneticsMutationMiddle AgedPhenotype3. Good healthTransmembrane domainclinical spectrum; epilepsy; HCN1; intellectual disability; ion channelintellectual disabilityChild PreschoolEpilepsy GeneralizedFemaleSpasms InfantileAdultAdolescentCHO CellsBiology03 medical and health sciencesYoung AdultCricetulusHCN1medicineAnimalsHumansGeneralized epilepsyGenetic Association StudiesAgedInfantmedicine.diseaseElectric Stimulationclinical spectrum030104 developmental biologyMutationion channelMutagenesis Site-DirectedepilepsyNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Cardiac phenotype in ATP1A3-related syndromes: A multicentre cohort study

2020

ObjectiveTo define the risks and consequences of cardiac abnormalities in ATP1A3-related syndromes.MethodsPatients meeting clinical diagnostic criteria for rapid-onset dystonia-parkinsonism (RDP), alternating hemiplegia of childhood (AHC), and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) with ATP1A3 genetic analysis and at least 1 cardiac assessment were included. We evaluated the cardiac phenotype in an Atp1a3 knock-in mouse (Mashl+/−) to determine the sequence of events in seizure-related cardiac death.ResultsNinety-eight patients with AHC, 9 with RDP, and 3 with CAPOS (63 female, mean age 17 years) were included. Resting ECG abnormalities…

medicine.medical_specialtyCerebellar ataxiaHeart blockbusiness.industryAlternating hemiplegia of childhood030204 cardiovascular system & hematologymedicine.disease3. Good healthSudden cardiac death03 medical and health sciences0302 clinical medicineAtrophyATP1A3Internal medicinemedicineCardiologyRepolarizationSensorineural hearing lossHuman medicineNeurology (clinical)medicine.symptombusinessBiology030217 neurology & neurosurgery
researchProduct

A de novo heterozygous mutation in KCNC2 gene implicated in severe developmental and epileptic encephalopathy

2020

Abstract An increasing number of developmental and epileptic encephalopathies have been correlated with variants of ion channel genes, and in particular of potassium channels genes, such as KCNA1, KCNA2, KCNB1, KCNQ2, KCTD7 and KCNT1. Here we report a child with an early severe developmental and epileptic encephalopathy, spastic tetraplegia, opisthotonos attacks. The whole exome sequencing showed the de novo heterozygous variant c.1411G > C (p.Val471Leu) in the KCNC2 gene. Although this is, to our knowledge, the first case of encephalopathy associated with a KCNC2 gene variant, and further confirmatory studies are needed, previous preclinical and clinical evidence seems to suggest that KCNC…

MaleKCNC2 geneKCTD7EncephalopathyBiologyEpilepsyGeneticsmedicineHumansExomeEEGChildGeneExomeSpastic tetraplegiaGenetics (clinical)Exome sequencingGeneticsEpilepsyKv3.2ElectroencephalographyDevelopmental and epileptic encephalopathieGeneral Medicinemedicine.diseaseKCNC2Shaw Potassium ChannelsNGSMutationEuropean Journal of Medical Genetics
researchProduct

Relapse risk factors in anti-N-methyl-D-aspartate receptor encephalitis

2019

Aim: To identify factors that may predict and affect the risk of relapse in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Method: This was a retrospective study of an Italian cohort of patients with paediatric (≤18y) onset anti-NMDAR encephalitis. Results: Of the 62 children included (39 females; median age at onset 9y 10mo, range 1y 2mo–18y; onset between 2005 and 2018), 21 per cent relapsed (median two total events per relapsing patient, range 2–4). Time to first relapse was median 31.5 months (range 7–89mo). Severity at first relapse was lower than onset (median modified Rankin Scale [mRS] 3, range 2–4, vs median mRS 5, range 3–5; admission to intensive care unit: 0/10 vs 3/10…

Male030506 rehabilitationGastroenterologyCohort Studies0302 clinical medicineRetrospective StudieModified Rankin ScaleRecurrenceRisk FactorsChildrelapseAnti-N-Methyl-D-Aspartate Receptor EncephalitisHazard ratioItalyChild PreschoolCohortanti‐N‐methyl‐D‐aspartate receptor encephalitisFemale0305 other medical scienceEncephalitisHumanCohort studymedicine.medical_specialtyAdolescentSocio-culturaleanti-NMDAR antibodies03 medical and health sciencesanti-NMDARDevelopmental NeuroscienceInternal medicinemedicineAdolescent; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Child; Child Preschool; Cohort Studies; Female; Humans; Infant; Italy; Male; Recurrence; Retrospective Studies; Risk FactorsHumansPreschoolSurvival analysisRetrospective StudiesAutoimmune encephalitisbusiness.industryInfantRetrospective cohort studymedicine.diseaseanti-NMDAR antibodies autoimmune encephalitis anti‐N‐methyl‐D‐aspartate receptor encephalitisautoimmune encephalitisAnti-N-methyl-D-aspartate receptor encephalitis anti-NMDAR autoimmune encephalitis relapseAnti-N-Methyl-D-Aspartate Receptor EncephalitiPediatrics Perinatology and Child HealthNeurology (clinical)Cohort Studiebusiness030217 neurology & neurosurgery
researchProduct

Letter to the Editor Regarding the Article Whole-Exome Sequencing in NF1-Related West's Syndrome Leads to the Identification of KCNC2 as a Novel Cand…

2020

Candidate geneShaw Potassium ChannelsLetter to the editorEpilepsybusiness.industryMEDLINEWest's syndromeGeneral MedicineComputational biologymedicine.diseaseSettore MED/39 - Neuropsichiatria InfantileEpilepsyShaw Potassium ChannelsPediatrics Perinatology and Child HealthExome SequencingMedicineHumansIdentification (biology)Neurology (clinical)businessSpasms InfantileExome sequencing
researchProduct